S&P to admit Imugene into ASX300 on Friday.

S&P will announce their September reweighting of the ASX300 this Friday 3 September 2021, and admit Imugene into the index.

Actual admission of new companies (and deletion of some existing companies) onto the ASX300 will take place on 17 September 2021.

S&P will announce their December reweighting of the ASX200 on Friday 3 December 2021 - and I fully expect Imugene to then be admitted into the ASX200.

Make no mistake, these changes are critically important for Imugene both on the domestic and international stage, and validate the company's position as one of Australia's leading biotech companies.

The positive impact of this recognition, both on the company's share price and on its global standing, should not be underestimated.